FORT LAUDERDALE, Fla., July 9, 2013 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTC:OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that Inflamax Research, a full service Contract Research Organization (CRO), has made a 5 year commitment to utilize OmniComm's eClinical SuiteTM to further enhance their clinical operations.
"Our team has a lot of experience with OmniComm's eClinical Suite and we are delighted to utilize it now at Inflamax Research," said Dr. Piyush Patel, CEO of Inflamax Research. "In addition to their innovative technology, we appreciate the exceptional technical support that OmniComm provides and their commitment to their clients. We have very similar philosophies and we look forward to this new partnership."
The OmniComm eClinical Suite is a comprehensive, functionally-rich solution that streamlines clinical trial processes and supports DDE and EDC within one system. It utilizes proven workflows that enable clinical operations to effectively plan each stage of a trial. The eClinical Suite is able to capture, manage, clean, export and lock trials quickly and cost-effectively.
"Inflamax Research is committed to scientific excellence in clinical research," stated Stephen Johnson, President and COO of OmniComm. "We value their partnership and are pleased they have chosen OmniComm's innovative solutions to help further enhance their clinical research operations."
About Inflamax Research
Inflamax Research, headquartered in Toronto, Canada, is a full service Contract Research Organization (CRO) specializing in Proof of Concept as well as Phase I through IV studies in allergy, asthma, ocular disease and dermatology, utilizing EEC technology. Inflamax conducts single and multi-center Environmental Exposure Chamber (EEC) and field studies.
About OmniComm Systems
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Kuno van der Post Ph.D OmniComm Systems, Inc. 954-473-1254 email@example.com
Source:OmniComm Systems Inc.